Supplemental figures

Figure S1. Western blot showing PTEN expression in PC-9, A549, H1299 and PC-3 cells.

Figure S2. Western blot showing Mre11 expression in H1650 and Mre11-transfected H1650 cells.

Figure S3. A: Subcellular localization of RPA and γH2AX in H1650 or $H1650^{PTEN+}$ cells after exposure of olaparib (20 μM). B: PTEN deficiency resulted in significant reduction in RPA focus formation after exposure of cisplatin (10 μM) or/and olaparib (20 μM), or irradiation (10 Gy) compared to $H1650^{PTEN+}$ cells ($P < 0.05$) although γH2AX was similarly increased in both cells.

Figure S4. Western blot analysis of cleaved-caspase 3 in H1650, $H1650^{PTEN+}$, PC-9 and $PC\text{-}9^{PTEN-}$ xenografts. The combination of cisplatin with olaparib seemed to have more cleaved-caspase 3 expressions than other treatments in H1650 and $PC\text{-}9^{PTEN-}$ xenografts, but not in PC-9 and $H1650^{PTEN+}$ xenografts.

Figure S5. Western blot showing RAD51 and RPA levels in H1650, $H1650^{PTEN+}$, PC-9 and $PC\text{-}9^{PTEN-}$ cells.